Literature DB >> 22216062

Management of dyslipidemia in HIV-infected patients.

Carlos D Malvestutto1, Judith A Aberg.   

Abstract

Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.

Entities:  

Year:  2011        PMID： 22216062      PMCID： PMC3249059          DOI： 10.2217/clp.11.25

Source DB:  PubMed          Journal:  Clin Lipidol        ISSN： 1758-4302


  104 in total

1.  Platelet function and HIV: a case-control study.

Authors:  Claudette S Satchell; Aoife G Cotter; Eileen F O'Connor; Aaron J Peace; Anthony F Tedesco; Andrew Clare; John S Lambert; Gerard J Sheehan; Dermot Kenny; Patrick W G Mallon
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

Review 2.  Switching strategies to improve lipid profile and morphologic changes.

Authors:  Patricia Barragan; Cesar Fisac; Daniel Podzamczer
Journal:  AIDS Rev       Date:  2006 Oct-Dec       Impact factor: 2.500

3.  Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities.

Authors:  J C Thomas; M F Lopes-Virella; V E Del Bene; J D Cerveny; K B Taylor; L S McWhorter; N C Bultemeier
Journal:  Pharmacotherapy       Date:  2000-06       Impact factor: 4.705

4.  Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Authors:  Jose Gatell; Dominique Salmon-Ceron; Adriano Lazzarin; Eric Van Wijngaerden; Francisco Antunes; Clifford Leen; Andrzej Horban; Victoria Wirtz; Linda Odeshoo; Monique Van den Dungen; Claudia Gruber; Emilio Ledesma
Journal:  Clin Infect Dis       Date:  2007-04-25       Impact factor: 9.079

5.  Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease.

Authors:  D M Aboulafia; R Johnston
Journal:  AIDS Patient Care STDS       Date:  2000-01       Impact factor: 5.078

6.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

7.  Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.

Authors:  Michael J Silverberg; Wendy Leyden; Leo Hurley; Alan S Go; Charles P Quesenberry; Daniel Klein; Michael A Horberg
Journal:  Ann Intern Med       Date:  2009-03-03       Impact factor: 25.391

8.  HIV infection and high density lipoprotein metabolism.

Authors:  Honor Rose; Jennifer Hoy; Ian Woolley; Urbain Tchoua; Michael Bukrinsky; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2007-12-04       Impact factor: 5.162

9.  European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

Authors:  J D Lundgren; M Battegay; G Behrens; S De Wit; G Guaraldi; C Katlama; E Martinez; D Nair; W G Powderly; P Reiss; J Sutinen; A Vigano
Journal:  HIV Med       Date:  2008-02       Impact factor: 3.180

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226
View more
  9 in total

1.  Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

Authors:  Benjamin Young; Kathleen E Squires; Lisa L Ross; Lizette Santiago; Louis M Sloan; Henry H Zhao; Brian C Wine; Gary E Pakes; David A Margolis; Mark S Shaefer
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-05       Impact factor: 2.205

2.  Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Res Hum Retroviruses       Date:  2018-11-27       Impact factor: 2.205

3.  HIV stroke risk: evidence and implications.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah L Commins; William Yong; Margrit Carlson
Journal:  Ther Adv Chronic Dis       Date:  2013-03       Impact factor: 5.091

4.  The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population.

Authors:  Cavin Epie Bekolo; Modestine Becker Nguena; Leonard Ewane; Patrick Sylvestre Bekoule; Basile Kollo
Journal:  BMC Public Health       Date:  2014-03-07       Impact factor: 3.295

5.  Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects.

Authors:  Adelzon A Paula; Melissa Cn Falcão; Antonio G Pacheco
Journal:  AIDS Res Ther       Date:  2013-12-13       Impact factor: 2.250

6.  Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.

Authors:  Kathleen E Squires; Benjamin Young; Lizette Santiago; Robin H Dretler; Sharon L Walmsley; Henry H Zhao; Gary E Pakes; Lisa L Ross; Mark S Shaefer
Journal:  HIV AIDS (Auckl)       Date:  2017-03-03

Review 7.  Atherosclerosis in HIV Patients: What Do We Know so Far?

Authors:  Anastasia V Poznyak; Evgeny E Bezsonov; Evgeny E Borisov; Andrey V Grechko; Andrey G Kartuesov; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

8.  The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study.

Authors:  Jun Hyoung Kim; Heeseon Jang; Jung Ho Kim; Joon Young Song; Shin-Woo Kim; Sang Il Kim; Bo Youl Choi; Jun Yong Choi
Journal:  Infect Chemother       Date:  2022-09

9.  Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study.

Authors:  Danai Tavonga Zhou; Olav Oektedalen; Sandra Shawarira-Bote; Babill Stray-Pedersen
Journal:  HIV AIDS (Auckl)       Date:  2016-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.